Search

Background: Invasive lobular carcinoma (ILC) differs from invasive ductal carcinoma (IDC) in genomic profile, clinicopathologic behavior, and response to treatment. Despite favorable profile, ILC is susceptible to recurrence. Thus, most of studies did not include ILC in intraoperative radiotherapy (IORT) trials or considered it as a cautionary criteria, especially in accelerated partial breast irradiation (APBI). Objectives: In this study, we compared treatment outcome between breast cancer patients with ILC and IDC treating with breast conserving surgery and intraoperative electron radiotherapy (IOERT). Methods: A total of 191 patients with early breast cancer treated with breast conserving surgery and IOERT were included in the study. This study compared outcome of 42 ILC patients with 135 IDC patients. Fourteen patients were mixed type. ILC was a suitable criterion, as well. Local recurrence and disease-free survival were endpoints of study. Results: Median follow-up was 23.17 month and 21.17 month for IDC and ILC, respectively. Univariate analysis was done according to age, pathologic, and biologic factors and multivariate analysis was according molecular subtype. There were 3 patients with local recurrence. Two patients were in the IDC group and another one was the ILC group. There was no significant difference between two groups. The 4-year disease-free survival (DFS) was 95.45% and 97.40% for ILC and IDC, respectively. Conclusions: In this study, there was no significant difference in in-breast tumor recurrence (IBTR) and DFS between two groups. It was seem lobular carcinoma can be used for APBI and it may be a suitable criterion as the IDC. [ABSTRACT FROM AUTHOR]

Background: Breast conserving surgery and its following radiotherapy is an accepted therapeutic method for patients with invasive lobular carcinoma (ILC). Objectives:We compared clinical outcomes of women diagnosed with ILC or invasive ductal carcinoma (IDC) treated with intraoperative electron radiotherapy (IOERT) boost dose and external beam radiotherapy (EBRT) as whole breast irradiation (WBI) versus EBRT as WBI. Methods: In this retrospective study including 632 patients, who were referred to cancer research center of Shahid Beheshti University from August 2013 to September 2017 and received IORT, after breast-conserving surgery, we compared prognostic factors and ipsilateral breast recurrence (IBR) and distant recurrence (metastasis); 426 patients received a tumor bed boost with IOERT during lumpectomy, 58 patients were pure invasive lobular carcinoma, and 239 patients were pure invasive ductal carcinoma. The patient followed-up to 49 months. We retrospectively analyzed the factors associated with interfering to effects of IOERT with boost dose in the patient with breast cancer. Results: At 4 years, there were 2 cases ipsilateral breast recurrence in the IDC boost IOERT group and 0 cases ILC boost group and there were 5 cases distance or metastatic breast recurrence in the IDC boost IOERT group, and 0 case ILC boost group. Conclusions: Overall, the rates of local recurrence and distant recurrence (metastasis) in the ILC boost IOERT group were signifi- cantly low and compared to the second group, they were not inferior. [ABSTRACT FROM AUTHOR]

Background: Recognizing complications, survival rates, and contributing factors would result in better diseases control in patients with thyroid cancer under thyroidectomy. Accordingly, this study was performed to determine the overall survival and complications in patients with thyroid cancer under thyroidectomy procedure. Methods: In this retrospective, 100 patients with thyroid cancer under thyroidectomy, who were admitted in the affiliated centers of cancer research centers at Shahid Beheshti University of Medical Sciences in recent 5 years from summer 2011 to summer 2016, were enrolled. Data collection was done by census sampling and the required data were collected via existing medical documents and were recorded by checklist from April 2016 to February 2017. Results: Thyroidectomy was total in 97% of the patients, and 3 were under subtotal thyroidectomy (two patients had anaplastic and 1 had micro papillary carcinoma). Twenty-four patients (24%) had some side effects, including no permanent nerve injury but transient nerve injury (Hoarseness) (14%), organ pressure due to hematoma (4%) and tracheal rupture (1%), and transient hypocalcaemia (5%). The recurrence and death were seen in 5% and 3%. The recurrence was related to side effects, but it was not related to death (P > 0.05). Conclusions: We studied overall survival and complications of thyroidectomy in 100 patients with thyroid cancer from summer 2011 to summer 2016 and compared them with statistics on the articles. Thyroidectomy completion is an important procedure in the treatment of a malignant thyroid tumor because of the high rate of contralateral involvement (23.8%). It is a procedure with zero mortality and very low complication rate, not bearing relevant risks. Totally, according to the obtained results in current study, it maybe concluded that thyroidectomy complications are seen in 1 out of 20 patients, especially neck hematoma (4%) and tracheal rupture (1%). The survival in current study is good. [ABSTRACT FROM AUTHOR]

Background: Breast cancer treatment success depends upon prolonging survival with effective treatment, and constant monitoring of recurrence. Survival rate can well be improved by better understanding of prognostic factors, preventive measures, and effective treatments together with follow-up and post-treatment care. Objectives: This study is aimed to know prognostic factors effective in recurrence and death in Iranian breast cancer patients. Methods: This is a retrospective study conducted by reviewing data acquired from 1604 female breast cancer patients who were admitted to Cancer Research Center at Shahid Beheshti University of Medical Sciences between October, 1982 and March, 2014. During the follow-up, after diagnosis, 313 patients experienced recurrence then were classified into two groups: early recurrence, less than 1 year and late recurrence after 5 years. We analyzed prognostic factors of recurrence in each groups and evaluated effective factors of death in this patients. Results: Median age of patients at diagnosis was 50 years. Median follow up time was 4.33 years (range: 0.005-24.9 years). Of these patients, 210 (67.09 %) and 76 (24.28%), developed distant and loco -regional recurrence. Among 313 patients, 62 (21/60%) and 69 (24/04%) had early and late recurrence. In the univariate analysis, tumor grade, stage of disease, ER and PR status, axillary lymph node involvement and lymph vascular invasion were the prognostic factors affecting recurrence in patients, but in the multivariate analysis, ER/PR status was the most important independent prognostic factor affecting the early recurrence and stage of disease were prognostic factors in late recurrence. In all of the recurrent patients, 56.86% (178 individuals) survived and 43.13% (135 individuals) died at the end of follow-up period. The most important factors of death were histologic grade, disease free survival time, site of recurrence and age of disease. Conclusions: Biologic marker, estrogen and progesterone receptors status, had most influence in early recurrence, unlike late recurrence, stage of disease had a more important role. However, lymph vascular invasion has been an effective factor either in early or late recurrence. As a result of studying effective factors in death of these patients, recurrence site, DFS, pathologic grade and patients' age at the time of recurrence came to be effective. Knowing more about affecting factors on recurrence and the death of patients with recurrence, one can try to enhance survival and quality of life in patients by adopting more effective treatments. [ABSTRACT FROM AUTHOR]